c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease.
Polycystic kidney disease is an inherited degenerative disease in which the uriniferous tubules are replaced by expanding fluid-filled cysts that ultimately destroy organ function. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form, afflicting approximately 1 in 1,000 peopl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-12-01
|
| Series: | PLoS Genetics |
| Online Access: | https://doi.org/10.1371/journal.pgen.1009711 |
| _version_ | 1797834657029423104 |
|---|---|
| author | Abigail O Smith Julie A Jonassen Kenley M Preval Roger J Davis Gregory J Pazour |
| author_facet | Abigail O Smith Julie A Jonassen Kenley M Preval Roger J Davis Gregory J Pazour |
| author_sort | Abigail O Smith |
| collection | DOAJ |
| description | Polycystic kidney disease is an inherited degenerative disease in which the uriniferous tubules are replaced by expanding fluid-filled cysts that ultimately destroy organ function. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form, afflicting approximately 1 in 1,000 people. It primarily is caused by mutations in the transmembrane proteins polycystin-1 (Pkd1) and polycystin-2 (Pkd2). The most proximal effects of Pkd mutations leading to cyst formation are not known, but pro-proliferative signaling must be involved for the tubule epithelial cells to increase in number over time. The c-Jun N-terminal kinase (JNK) pathway promotes proliferation and is activated in acute and chronic kidney diseases. Using a mouse model of cystic kidney disease caused by Pkd2 loss, we observe JNK activation in cystic kidneys and observe increased nuclear phospho c-Jun in cystic epithelium. Genetic removal of Jnk1 and Jnk2 suppresses the nuclear accumulation of phospho c-Jun, reduces proliferation and reduces the severity of cystic disease. While Jnk1 and Jnk2 are thought to have largely overlapping functions, we find that Jnk1 loss is nearly as effective as the double loss of Jnk1 and Jnk2. Jnk pathway inhibitors are in development for neurodegeneration, cancer, and fibrotic diseases. Our work suggests that the JNK pathway should be explored as a therapeutic target for ADPKD. |
| first_indexed | 2024-04-09T14:42:03Z |
| format | Article |
| id | doaj.art-26217d00b81a43db9143c50e1381457f |
| institution | Directory Open Access Journal |
| issn | 1553-7390 1553-7404 |
| language | English |
| last_indexed | 2024-04-09T14:42:03Z |
| publishDate | 2021-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Genetics |
| spelling | doaj.art-26217d00b81a43db9143c50e1381457f2023-05-03T05:31:04ZengPublic Library of Science (PLoS)PLoS Genetics1553-73901553-74042021-12-011712e100971110.1371/journal.pgen.1009711c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease.Abigail O SmithJulie A JonassenKenley M PrevalRoger J DavisGregory J PazourPolycystic kidney disease is an inherited degenerative disease in which the uriniferous tubules are replaced by expanding fluid-filled cysts that ultimately destroy organ function. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form, afflicting approximately 1 in 1,000 people. It primarily is caused by mutations in the transmembrane proteins polycystin-1 (Pkd1) and polycystin-2 (Pkd2). The most proximal effects of Pkd mutations leading to cyst formation are not known, but pro-proliferative signaling must be involved for the tubule epithelial cells to increase in number over time. The c-Jun N-terminal kinase (JNK) pathway promotes proliferation and is activated in acute and chronic kidney diseases. Using a mouse model of cystic kidney disease caused by Pkd2 loss, we observe JNK activation in cystic kidneys and observe increased nuclear phospho c-Jun in cystic epithelium. Genetic removal of Jnk1 and Jnk2 suppresses the nuclear accumulation of phospho c-Jun, reduces proliferation and reduces the severity of cystic disease. While Jnk1 and Jnk2 are thought to have largely overlapping functions, we find that Jnk1 loss is nearly as effective as the double loss of Jnk1 and Jnk2. Jnk pathway inhibitors are in development for neurodegeneration, cancer, and fibrotic diseases. Our work suggests that the JNK pathway should be explored as a therapeutic target for ADPKD.https://doi.org/10.1371/journal.pgen.1009711 |
| spellingShingle | Abigail O Smith Julie A Jonassen Kenley M Preval Roger J Davis Gregory J Pazour c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. PLoS Genetics |
| title | c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. |
| title_full | c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. |
| title_fullStr | c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. |
| title_full_unstemmed | c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. |
| title_short | c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. |
| title_sort | c jun n terminal kinase jnk signaling contributes to cystic burden in polycystic kidney disease |
| url | https://doi.org/10.1371/journal.pgen.1009711 |
| work_keys_str_mv | AT abigailosmith cjunnterminalkinasejnksignalingcontributestocysticburdeninpolycystickidneydisease AT julieajonassen cjunnterminalkinasejnksignalingcontributestocysticburdeninpolycystickidneydisease AT kenleympreval cjunnterminalkinasejnksignalingcontributestocysticburdeninpolycystickidneydisease AT rogerjdavis cjunnterminalkinasejnksignalingcontributestocysticburdeninpolycystickidneydisease AT gregoryjpazour cjunnterminalkinasejnksignalingcontributestocysticburdeninpolycystickidneydisease |